145 having a care giver; clinicians’ responsiveness to other factors such as providing quality treatments that cause an improved transition in health, ensuring that patients are satisfied with the care they receive, and managing side effects could lead to patients’ improved vitality, general and mental health. Lastly, baseline factors such as AIDS-defining illnesses, HBV co-infection and prior ARV experience should be borne in mind when reviewing response to treatment through the objective assessment of CD4 cell counts, viral load and HIV-related clinical events;
as this will better inform clinical decision-making.
146 REFERENCES
1. Hays RD, Sherbourne CD, Mazel R. User's Manual for the Medical Outcomes Study (MOS) Core Measures of Health-Related Quality of Life. Rand Monograph Report:
1995. Available at http://www.rand.org/pubs/monograph_reports/MR/162/. Accessed on April 3, 2008.
2. Hays RD, Cunningham WE, Sherbourne CD, Wilson IB, Wu AW, Cleary PD, McCaffrey DF, Fleishman JA, Crystal S, Collins R, Eggan F, Shapiro MF, Bozzette SA. Health-related quality of life in patients with human immunodeficiency virus infection in the United States: results from the HIV Cost and Services Utilization Study. Am J Med., 2000; 108: 714–722.
3. Berzon RA, William RL. Evaluating the outcomes of HIV disease: focus on health status measurement. A publication for Members of Medical Outcomes Trust. 1998; 3 (4).
Available at www.outcomes-trust.org/monitor/1198mon.htm. Accessed on 3 April, 2008.
4. Cunningham WE, Crystal S, Bozzette S, Hays RD. The Association of health-related quality of life with survival among persons with HIV Infection in the United States. J Gen Intern Med, 2005; 20: 21–27.
5. Marquis P, Arnould B, Acquadro C, Roberts WM. Research Commentary. Patient-reported outcomes and health-related quality of life in effectiveness studies: pros and cons. Drug Dev. Res, 2006; 67: 193–201.
6. Thaczuk D. Living with HIV in France in the 21st century: employment, response to treatment, and quality of life. 2006. Available at www.aidsmap.com/en/news/4C4D26E6-AB83-4537-8AE9-F8F3733AE3D8.asp?type=preview. Accessed on April 3, 2008.
147 7. Cipla Doc. HIV/AIDS. A clinician’s guide. 2000. Available at www.cipladoc.com/publications/aidupdate/hivaids/hivaids1.htm. Accessed on April 3,
2008.
8. Leusaree T, Khemngern P, Wiboolsanti S, Siri S, Vitsupakorn K, Dettrairat S, Panpanich R. Outcomes of HAART program in Northern Thailand. Int Conf AIDS, 2004 Jul 11-16, 15: abstract no. WeOrB1315.
9. Ekong E. The Nigerian accelerated antiretroviral drug initiative – evaluation of nevirapine, lamivudine and stavudine in ARV naive patients. IAS Conf HIV Pathog Treat, 2003 Jul 13-16, 2nd: abstract no. 629.
10. Idigbe EO. The use of generic copies of ARVs in the management of HIV infections in Lagos, Nigeria: a 6 month follow-up study. IAS Conf HIV Pathog Treat, 2003 Jul 13-16, 2nd: abstract no. 697.
11. Wenkel J, O’Brien DP, Chan K, van den Boogaard W, Botha Standaert E, Braker K, Olaiya MA, Guenther G, Grillo AG, Olomo BA, Mills C. A comparison of the virological and immunological outcomes of ARV-naive and ARV-experienced patients on 2003 WHO-recommended first-line ART. Available at www.msf.ca/aids2006.
Accessed on April 3, 2008.
12. Kalichman SC, Ramachandran B, Catz S. Adherence to combination antiretroviral therapies in HIV patients of low health literacy. J Gen Intern Med, 1999; 14(5): 267-273.
13. Detels R, Munoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, Schrager LK, Phair JP. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA, 1998; 280 (17): 1497-1503.
148 14. Egger M Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, Rickenbach M, Maliverni R, Vernazza P, Battegay M. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ, 1997; 315 (7117):
1194-1199.
15. Hogg RS, O’Shaughnessy MV, Gataric N, Yip B, Craib K, Schechter MT Montaner JS.
Decline in deaths from AIDS due to new antiretrovirals. Lancet, 1997; 349 (9061):1294.
16. Lee LM, Karon JM, Selik R, Neal JJ, Fleming PL. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997. JAMA, 2001;
285 (10): 1308-1315.
17. Mouton Y, Alfandari S, Valette M, Cartier F, Dellamonica P, Humbert G, Lang JM, Massip P, Mechali D, Leclerq P, Modai J, Portier H. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centers. AIDS, 1997; 11 (12): F 101-F105.
18. Pallela FJ Jr, Delaney KM, Movrman AC, Loveless MO, Fuhrer J, Satten GA Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigations. N. Engl J Med, 1998; 338 (13): 853-860.
19. Wu AW, Gifford A, Asch S, Cohn SE, Bozzette SA, Yurk R. Quality of care indicators for HIV/AIDS. Dis Manage Health Outcomes, 2000; 7 (6): 315-330.
20. Odutola O, Mafeni JO, Okonkwo P, Fajemisin OA. Monitoring and evaluation of HIV/AIDS in Nigeria. In: Adeyi O, Kanki PJ, Odutola O, Idoko JI, eds. AIDS in Nigeria.
A nation on the threshold. Cambridge: Harvard Centre for Population and Development Studies, 2006: 537-558.
149 21. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2006 report on the global AIDS epidemic: Executive summary. A Joint United Nations Programme on HIV/AIDS (UNAIDS) 10th anniversary special edition. Available at www.unaids.org. Accessed on March 3, 2007.
22. Federal Ministry of Health (FMOH). Situation of ARV drug use in Nigeria. Abuja:
FMOH, 2003.
23. World Health Organization (WHO). Estimated number of people receiving ARV therapy and percentage coverage in 20 countries with the highest unmet need in June 2005.
Geneva: WHO, 2006a. Available at www.who.int/hiv/facts/20UNMETNEEDweb.jpg.
Accessed on March 7, 2006.
24. Global HIV/AIDS Initiative Nigeria (GHAIN). GHAINing Ground. A Newsletter from the Global HIV/AIDS Initiative Nigeria. April 2007. Available at www.fhi.org/.../GHAINingGroundApril2007. Accessed on July 23, 2007.
25. President’s emergency plan for AIDS relief (PEPFAR). 2007 country profile: Nigeria.
Available at www.pepfar.gov/documents/organization/101660.pdf. Accessed on July 23, 2007.
26. Grabar S, Le Moing V, Goujard C, Leport C, Kazatchkine MD, Costagliola D, Laurence W. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 Months of highly active antiretroviral therapy. Ann Intern Med, 2000; 133: 401-410.
27. Horizons/Population Council. Adherence to antiretroviral therapy in adults: a guide for trainers. International Centre for Reproductive Health and Coast Province General Hospital, Mombasa – Kenya, 2004. Nairobi: Population Council.
150 28. Robberstad B, Olsen JA. The health related quality of life of people living with HIV/AIDS in sub-Saharan Africa - a literature review and focus group study. Cost Eff Resourc Alloc, 2010; 8: 5.
29. Saunders DS and Burgoyne RW. Evaluating health-related wellbeing outcomes among outpatient adults with human immunodeficiency virus infection in the HAART era. Int J STD AIDS, 2002; 13 (10): 683-690.
30. Liu C, Weber K, Robison E, Hu Z, Jacobson LP, Gange SJ. Assessing the effect of HAART on change in quality of life among HIV-infected women. AIDS Research and Therapy, 2006; 3: 6.
31. Badia X, Podzamczer D, Casado A, Lopez-Lavid C, Garcia M: Evaluating changes in health status in HIV-infected patients: Medical Outcomes Study-HIV and Multidimensional Quality of Life-HIV quality of life questionnaires. Spanish MOS-HIV and MQOL-HIV Validation Group. AIDS, 2000; 14: 1439-1447.
32. Gill CJ, Griffith JL, Jacobson D, Skinner S, Gorbach SL, Wilson IR. Relationship of HIV viral loads, CD4 counts, and HAART use to health-related quality of life. J Acquir Immune Defic Syndr, 2002; 30: 485-492.
33. Jelsma J, Maclean E, Hughes J, Tinise X, Darder M: An investigation into the health-related quality of life of individuals living with HIV who are receiving HAART. AIDS Care, 2005; 17(5):579-588.
34. Tramarin A, Campostrini S, Postma MJ, Calleri G, Tolley K, Parise N, de Lalla F, The Palladio Study Group: A multicentre study of patient survival, disability, quality of life and cost of care among patients with AIDS in northern Italy. Pharmacoeconomics, 2004;
22: 43-53.
151 35. Carrieri P, Spire B, Duran S, Katlama C, Peyramond D, François C, Chêne G, Lang J-M, Moattie J-P, Leport C, and the APROCO Study Group: health-related quality of life after 1 year of highly active antiretroviral therapy. J Acquir Immune Defic Syndr, 2003; 32:
38-47.
36. Braitstein P, Brinkhof MWG, Dabis F, Schechter M, Boulle A, Miotti P, Wood R, Laurent C, Sprinz E, Seyler C, Bangsberg DR, Balestre E, Sterne JAC, May M, Egger M.
Mortality of HIV-1 infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet, 2006; 367: 817-827.
37. Kitchen CM, Kitchen SG, Dubin JA, Gottlieb MS. Initial virologic and immunologic response to highly active antiretroviral therapy predicts long-term clinical outcome. Clin Infect Dis, 2001; 33: 466-472.
39. Springer SA, Pesanti E, Hodges J, Macura T, Doros G, Altice FL. Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community. Clin Infect Dis, 2004; 38: 1754-1760.
40. Gange SJ, Barrón Y, Greenblatt RM, Anastos K, Minkoff H, Young M, Kovacs A, Cohen M, Meyer WA, and Muñoz A. Effectiveness of highly active antiretroviral therapy among HIV-1 infected women. J. Epidemiol. Community Health, 2002; 56: 153-159.
152 41 Hogg RS, Yip B, Kully C, Craib KJP, O’Shaughnessy MV, Schechter MT, Montaner JSG. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ, 1999; 160: 659–665.
42. Velasco M, Gomez A, Fernandez C, Perez-Cecilia E, Tellez MJ, Roca V, Fernandez-Cruz A. Economic impact of HIV protease inhibitor therapy in the global use of health-care resources. HIV Med, 2000; 1: 246-251.
43. Idoko, JA, Agbaji O, Agaba P, Akolo C, Inuwa B, Hassan Zuweira, Akintunde L, Badung B, Muazu M, Danang M, Imade G, Sankale J Louis, Kanki, Phyllis. Direct observation therapy-highly active antiretroviral therapy in a resource-limited setting: the use of community treatment support can be effective. Int J STD AIDS, 2007; 18 (11):
760-763.
44. Hays RD, Spritzer KL, McCaffrey D, Cleary PD, Collins R, Sherbourne C, Wu AW, Bozzette S, Shapiro M, Cunningham W, Eggan F, Crysta S, Fleishman J. The HIV cost and services utilization (HCSUS) measures of health-relatedn quality of life. Available at www.rand.org/health/surveys_tools. Accessed on April 3, 2008.
45. Levine S. The changing terrains in medical sociology: Emergent concern with quality of life. J Health Soc Behavior, 1987; 28: 1-6.
46. Ware JE Jr and Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36) I.
Conceptual framework and item selection. Med Care, 1992; 30(6): 473-483.
47. Revicki DA, Sorensen S and Wu AW. Reliability and validity of physical and mental health summary scores from the Medical Outcomes Study HIV Health Survey. Med Care, 1998; 36(2): 126-137.
153 48. Herrmann S, McKinnon E, Hyland NB, Lalanne C, Mallal S, Chassany O, Duracinsky M, Nolan D. HIV-related stigma and physical symptoms have a persistent influence on health-related quality of life in Australians with HIV infection. Health Qual Life Outcomes, 2013; 11: 56.
49. World Health Organization (WHO), 2002. WHOQOL-HIV instrument: User’s manual.
Scoring and coding for the WHOQOL-HIV instruments. Available at http://www.who.int/mental_health/media/en/613.pdf. Accessed on May 20, 2014.
50. World Health Organization (WHO), 1996. WHOQOL-BREF. Introduction, Administration, Scoring and Generic version of the Assessment. Field Trial Version.
Available at http://www.who.int/mental_health/media/en/76.pdf. Accessed on May 20, 2014.
51. Sen SS, Gupchup GV, Thomas J 3rd. Selecting among health-related quality-of-life instruments. Am J Health Syst Pharm, 1999; 56(19): 1965-1970.
52. Kirshner B, Guyatt G. A methodological framework for assessing health indices. J Chronic Dis, 1985; 38(1): 27-36.
53. Shahriar J, Delate T, Hays RD, Coons SJ. Commentary on using the SF-36 or MOS-HIV in studies of persons with HIV disease. Health Qual Life Outcomes, 2003; 1: 25.
54. French K. Methodological considerations in hospital patient opinion surveys.
International Journal of Nursing Studies 40 (2003) 525–541
55. Murri R, Fantoni M, Del Borgo C, Visona R, Barracco A, Zambelli A, Testa L, Orchi N, Tozzi V, Bosco O, Wu AA. Determinants of health-related quality of life in HIV-infected patients. AIDS Care, 2003; 15 (4): 581-590.
154 56. de Boer-van der Kolk IM, Sprangers MA, Prins JM, Smit C, de Wolf F, Nieuwkerk PT.
Health-Related Quality of Life and Survival among HIV-Infected patients receiving highly active antiretroviral therapy: a study of patients in the AIDS Therapy Evaluation in the Netherlands (ATHENA) Cohort. Clin Infect Dis, 2010; 50(2): 255–263.
57. Peter E, Kamath R, Andrews T, Hegde BM. Psychosocial determinants of health-related quality of life of people living with HIV/AIDS on antiretroviral therapy at Udupi district, Southern India. Int J Prev Med, 2014; 5: 203-209.
58. Bello SI, Bello IK. Quality of life of HIV/AIDS patients in a secondary health care facility, Ilorin, Nigeria. Proc Bayl Univ Med Cent, 2013; 26(2): 116-119.
59. Folasire OF, Irabor AE, Folasire AM. Quality of life of people living with HIV and AIDS attending the antiretroviral clinic, University College Hospital, Nigeria. Afr J Prm Health Care Fam Med, 2012; 4(1), Art. #294, 8 pages.
http://dx.doi.org/10.4102/phcfmv4i1.294.
60. Fatiregun AA, Mofolorunsho KC, Osagbemi KG. Quality of life of people living with HIV/AIDS in Kogi State, Nigeria. Benin Journal of Postgraduate Medicine, 2009; 11(1):
21-27.
61. Mbada CE, Onayemi O, Ogunmoyole Y, Johnson OE, Akosile CO. Health-related quality of life and physical functioning in people living with HIV/AIDS: a case–control design. Health Qual Life Outcomes, 2013; 11: 106.
62. Adedimeji AA and Odutolu O. Care support and quality of life outcomes among persons living with HIV in the HAART era: findings from southwest Nigeria 2005. Available at www.hsph.harvard.edu/takemi/RP227.pdf. Accessed on April 13, 2008.
155 63. Jaquet A, Garanet F, Balestre E, Ekouevi DK, Azani JC, Bognounou R, Dah E, Kondombo JC, Dabis F, Drabo J. Antiretroviral treatment and quality of life in Africans living with HIV: 12-month follow-up in Burkina Faso. J Int AIDS Soc, 2013; 16:18867.
doi:10.7448/IAS.16.1.18867.
64. Louwagie GM, Bachmann MO, Kobus M, le R Booysen F, Fairall LR, Heunis C. Highly active antiretroviral treatment and health related quality of life in South African adults with human immunodeficiency virus infection: a cross-sectional analytical study. BMC Public Health, 2007; 7: 244.
65. Mutimura E, Stewart A, Crowther NJ. Assessment of quality of life in HAART-treated HIV-positive subjects with body fat redistribution in Rwanda. AIDS Res Ther, 2007;
18(4): 19.
66. Preau M, Marcellin F, Carrieri MP, Lert F, Obadia Y, Spire B, and the VESPA Study Group. Health-related quality of life in French people living with HIV in 2003: results from the national ANRS-EN12-VESPA Study. AIDS, 2007; 21 (Suppl.1): S19–S27.
67. Preau M, Apostolidis T, Francois C, Raffi F, Spire B. Time perspective and quality of life among HIV-infected patients in the context of HAART. AIDS Care, 2007; 19(4): 449-458.
68. Jia H, Uphold CR, Wu S, Chen GJ, Duncan PW. Predictors of changes in health-related quality of life among men with HIV infection in the HAART era. AIDS Patient Care STDS, 2005; 19(6): 395-405.
69. Campsmith ML, Nakashima AK, Davidson AJ. Self-reported health-related quality of life in persons with HIV infection: results from a multi-site interview project. Health Qual Life Outcomes, 2003; 1: 12.
156 70. Degroote S, Vogelaers DP, Vermeir P, Mariman A, De Rick A, Van Der Gucht B, Pelgrom J, Van Wanzeele F, Verhofstede C, Vandijck DM. Socio-economic, behavioural, (neuro)psychological and clinical determinants of HRQoL in people living with HIV in Belgium: a pilot study. J Int AIDS Soc, 2013; 16: 18643. doi: 7448/IAS.16.1.18643.
71. Tran BX, Ohinmaa A, Nguyen LT. Quality of life profile and psychometric properties of the EQ-5D-5L in HIV/AIDS patients. Health Qual Life Outcomes, 2012; 10: 132.
72. Tran BX. Quality of life outcomes of antiretroviral treatment for HIV/AIDS patients in Vietnam. PLoS One, 2012; 7(7) e41062.
73. Munene E, Ekman B. Does duration on antiretroviral therapy determine health-related quality of life in people living with HIV? A cross-sectional study in a regional referral hospital in Kenya. Glob Health Action, 2014; 7: 23554.
http://dx.doi.org/10.3402/gha.v7.23554.
74. Alemu A, Yenealem A, Feleke A, Meseret S. Health related quality of life assessment and associated factors among people on highly active antiretroviral therapy at Felege Hiwot Referral Hospital, Bahir Dar, North West Ethiopia. J AIDS Clin Res, 2013; 5 (1):
1000272. http://dx.doi.org/10.4172/2155-6113.1000272.
75. Department of Health and Human Services (DHHS). Panel on antiretroviral guidelines for adult and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 29,
2008;1-128. Available at
http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed on 4 April, 2008.
157 76. Bartlett, JG. Pocket guide. Adult HIV/AIDS treatment. January, 2006. Available at
http://www.hopkins-aids.org. Accessed on April 4, 2008.
77. Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, Hirschel B, Ledergerber B, Vernazza P, Bernasconi E, Rickenbach M, Egger M, Battegay M; Swiss HIV Cohort Study Group. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med, 2003; 163(18): 2187-2195.
78. Lau B, Gange SJ, Moore RD. Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm3. J Acquir Immune Defic Syndr, 2007; 44(2): 179-187.
79. Department of Health and Human Services (DHHS) and the Henry J Kaiser Family Foundation 2002. Guidelines for the use of antiretroviral agents in HIV- infected adults and adolescents. Available at http://www.hivatis.org/guidelines/adult. Accessed on April 13, 2006.
80. Federal Ministry of Health (FMOH). Guidelines for the use of antiretroviral (ARV) drugs in Nigeria. Abuja: Federal Ministry of Health, 2005.
81. Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis, 2007; 44: 441–446.
82. Liu ZY, Guo FP, Han Y, Qiu ZF, Zuo LY, Li YL, Li TS. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study. Chin Med J (Engl), 2009;
122(20): 2497-2502.
158 83. Musa BM, Gebi U, Etiebet M, Omuh H, Ekedegwa P, Dakum P, Blattner W.
Immunological profile in persons under antiretroviral therapy in a rural Nigerian hospital.
J Public Health Africa, 2010; 1: e3.
84. Kilaru KR, Kumar A, Sippy N, Carter AO, Roach TC. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country. HIV Medicine, 2006; 7: 99–104.
85. Lawn SD, Myer L, Bekker L, Wood R. CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa. BMC Infect Dis, 2006; 6: 59.
86. Ndwapi N. Preliminary analysis of mortality and causes of death among the first ARV-treatment naive HIV-1C-infected persons receiving HAART under the Botswana national ARV treatment program. IAS Conf HIV Pathog Treat, 2003 Jul 13-16, 2nd: abstract no.
1212.
87. Mougnutou R, Evaluation of a HAART pilot study in Yaounde, Cameroon: 24 months follow-up. IAS Conf HIV Pathog Treat, 2003 Jul 13-16, 2nd: abstract no. 686.
88. Kebba A. Therapeutic responses to AZT+3TC+EFV in advanced ARV-naive HIV-1 infected Ugandans. IAS Conf HIV Pathog Treat, 2003 Jul 13-16, 2nd: abstract no. 693.
89. Kibangou N. Pointe-Noire, Congo-Brazzaville: ARV therapy assessment, an evaluation following 6 months of prescription. IAS Conf HIV Pathog Treat, 2003 Jul 13-16, 2nd:
abstract no. 700.
90. Rastegar DA, Fingerhood MI, Jasinski DR. Highly active antiretroviral therapy outcomes in a primary care clinic. AIDS Care, 2003; 15 (2): 231-237.
159 91. Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Rickenbach M, Hirschel B, Battegay M, and the Swiss HIV Cohort Study.
Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/µL in HIV type 1–infected individuals receiving potent antiretroviral therapy. Clin Infect Dis, 2005; 41: 361–372.
92. Oette M, Kroidl A, Gobels K, Stabbert J, Menge M, Sagir A, Kuschak D, O’Hanley T, Bode JG, Haussinger D. Predictors of short-term success of antiretroviral therapy in HIV infection. J Antimicrob Chemother, 2006; 58: 147–153.
93. Breton G, Lewden C, Spire B, Salmon D, Brun-Vezinet F, Duong M, Allavena C, Leport C, and the APROCO COPILOTE ANRS CO8 Study Group. Characteristics and response to antiretroviral therapy of HIV-1-infected patients born in Africa and living in France.
HIV Medicine, 2007; 8: 164–170.
94. Erhabor O, Ejele AO, Uko EK. HAART-dependent CD4+ lymphocyte response based on pre-Therapeutic CD4 lymphocyte count in HIV-infected Nigerians. Annals of African Medicine, 2006; 5(3): 153-157.
95. Tuboi SH, Brinkhof MWG, Egger M, Stone RA, Braitstein P, Nash D, Sprinz E, Dabis F, Harrison LH, Schechter M. Discordant responses to potent antiretroviral treatment in previously naive HIV-1–infected adults initiating treatment in resource-constrained countries. J Acquir Immune Defic Syndr, 2007; 45(1): 52–59.
96. World Health Organization (WHO). Interim WHO clinical staging of HIV/AIDS and case definitions for surveillance. African Region. Geneva: WHO, 2005.
160 97. DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med, 2000;
133(6): 447-54.
98. Hirsch HH, Kaufmann G, Sendi P, Battegay M. Immune reconstitution in HIV-infected patients. Clin Infect Dis, 2004; 38(8): 1159-1166.
99. Iroezindu MO, Ofondu EO, Hausler H, van Wyk B. Prevalence and risk factors for opportunistic infections in HIV patients receiving antiretroviral therapy in a resource-limited setting in Nigeria. J AIDS Clinic Res, 2013; S3: 002. doi:10.4172/2155-6113.S3-002.
100. Azondekon A, HAART in Benin initiative: what have been used and for whom? Lessons from 448 patients elected one year later. IAS Conf HIV Pathog Treat, 2003 Jul 13-16;
2nd: abstract no. 636.
101. Ekong E, for the Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration. The risk of tuberculosis following HAART initiation among adults in resource-constrained settings. PEPFAR Implementers Meeting, June 12-15, 2006.
Durban, South Africa. Poster 45 – Treatment.
102. Jensen-Fangel S, Pedersen L, Pedersen C, Larsen CS, Tauris P, Møller A, Sørensen HT, Obel N. The effect of race/ethnicity on the outcome of highly active antiretroviral therapy for Human Immunodeficiency Virus Type 1–infected patients. Clin Infect Dis, 2002; 35:
1541–1548.
103. Federal Republic of Nigeria. Main findings of Census 2006 provisional results. Official Gazette. No 4, vol. 94. Government notice No 3. Lagos: Federal Republic of Nigeria, 2007 January 19: B 52.